GlassScriptPhysician profile
Matthew Loughlin
NPI 1255307401
$4,548.07
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.42 · 2020: $31.83 · 2021: $1,201 · 2022: $840 · 2023: $2,307 · 2024: $69.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,498 · Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,497.79 |
| Food and Beverage | $878.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,393.67 | 2021-2023 | Spaceoar System, Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $222.12 | 2019-2023 | Myrbetriq, Xospata |
| Janssen Biotech, INC. | $143.74 | 2019-2023 | Erleada |
| Pfizer INC. | $142.13 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $138.63 | 2021-2024 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $130.29 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $124.12 | 2022-2023 | Keytruda, Lynparza |
| Octapharma USA, INC. | $110.23 | 2021-2023 | Octagam Immune Globulin (Human) |
| Myriad Genetic Laboratories, INC. | $103.04 | 2021-2023 | Prolaris |
| Medtronic, INC. | $82.17 | 2023 | Interstim |
| Genzyme Corporation | $72.69 | 2021-2023 | |
| Seagen INC. | $68.21 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $67.96 | 2019-2023 | Edex, Xiaflex, Aveed |
| Axonics, INC. | $61.42 | 2023 | Axonics, Bulkamid |
| Exelixis INC. | $50.41 | 2021-2023 | Cabometyx |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Loughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.